AbbVie’s Blockbuster Vraylar Adds Significant Indication, Adjunctive MDD

 
• By Joseph Haas

Already selling at a run rate above $2bn annually, AbbVie predicts the atypical antipsychotic could reach the $4bn mark with a new US indication for adjunctive treatment of major depressive disorder.

FDA approved
Adjunctive MDD is Vraylar's fourth US label indication • Source: Shutterstock

More from New Products

More from Scrip